You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,999,339


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,999,339
Title:Methods for treating chronic obstructive pulmonary disease
Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.
Inventor(s): Risk; Clifford G. (Marlborough, MA)
Assignee:
Application Number:14/298,364
Patent Claims:1. A method of treating a mammal having COPD comprising administering to the mammal a therapeutically effective amount of a composition comprising an anti-immunoglobulin E (IgE) antibody; wherein the anti-IgE antibody reduces or blocks the binding of soluble IgE to its receptors, wherein the administration results in an outcome comprising a reduction in the number of acute exacerbations experienced by the mammal, and wherein the composition is free of steroids.

2. The method according to claim 1, wherein the anti-lgE antibody is a humanized IgG antibody that selectively binds to human IgE.

3. The method according to claim 2, wherein the humanized IgG antibody that selectively binds to human IgE is a monoclonal antibody.

4. The method according to claim 1, wherein the anti-lgE antibody is Omalizumab.

5. The method according to claim 1, wherein the mammal has an elevated serum IgE level.

6. The method according to claim 1, wherein the mammal has a negative skin test.

7. The method according to claim 1, wherein the mammal has a negative in vitro reactivity to a perennial aero allergen.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.